FDA approves Apidra for pediatric use

Article

The US Food and Drug Administration (FDA) has approved insulin glulisine (Apidra) to treat diabetes in children ages 4 and older, announced the drug's manufacturer, sanofi-aventis.

The US Food and Drug Administration has approved insulin glulisine (Apidra) to treat diabetes in children ages 4 and older, announced the drug's manufacturer, sanofi-aventis.

The approval is based on an FDA review of a 26-week, phase III, open-label study comparing Apidra with insulin lispro among 572 children ages 4 to 17 with type 1 diabetes. Changes in HbA1c were similar in both treatment groups (+0.10% for glulisine vs. +0.16% for lispro), as was postprandial glycemic control during endpoint.

Additionally, 7.2% of participants in the glulisine group and 8.1% of participants in the lispro group reported the adverse event of hypoglycemia, according to the manufacturer.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
© 2025 MJH Life Sciences

All rights reserved.